Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 3

Sponsor Class

INDUSTRY 30OTHER 23NIH 10NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1

Interventions

Specimen Handling 38Magnetic Resonance Spectroscopy 33Biopsy 16Radiation 15Cyclophosphamide 15Radiotherapy 14Vincristine 12Leucovorin 11Dexamethasone 11Carboplatin 11Etoposide 10Cisplatin 10Cytarabine 9Calcium Dobesilate 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Fluorouracil 8X-Rays 7Standard of Care 7Radiotherapy, Intensity-Modulated 7Practice Guidelines as Topic 7Platinum 7Doxorubicin 71,2-diaminocyclohexaneplatinum II citrate 7merphos 6dehydroftorafur 6Taxes 6Methotrexate 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Lenalidomide × 30 days × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT04566328 2026-05-15

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Eastern Cooperative Oncology Group

Phase 3 Recruiting
1,450 enrolled
Plasma cell

Multiple Myeloma

NCT06182774 2026-05-12

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Canadian Cancer Trials Group

Phase 3 Recruiting
570 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡